[Immunohistochemistry in Pancreatic Cancer with New Monoclonal Antibodies]

Overview

Journal Langenbecks Arch Chir

Specialty General Surgery

Date 1987 Jan 1

PMID 2830443

Citations 2

Authors

R Kubel

M Buchler

K Baczako

H G Beger

Affiliations

Soon will be listed here.

Abstract

Immunhistochemistry using hybridoma-derived monoclonal antibodies (MAb's) directed against tumor associated antigens offers new approaches to morphological diagnosis of tumors, e.g. for classification and typing of tumor subtypes with different prognosis. Before in-vivo application of monoclonal antibodies in man for diagnostic or therapeutic purposes the tissue distribution of the antibody should be determined immunhistochemically for assessment of antibody sensitivity and specificity. The binding capacity of the newly developed MAb BW 494/32 to pancreatic cancer tissues was therefore tested by immunhistochemistry, other benign and malignant intestinal and extraintestinal tissues served as controls. The MAb BW 494/32 showed positive immunoreactivity in all cases of ductal pancreatic adenocarcinomas grading I to II (sensitivity: 100%). In grading III carcinomas the target antigen was only accessible in half of the tested specimens. Specificity was limited by a mostly weak immunoreactivity with normal pancreas tissue in 36%, with acute inflamed tissue in 100%, with inflamed tissue in chronic pancreatitis in 71%. Extrapancreatic specificity was restricted by positive antibody binding to singular goblet cells of gastrointestinal epithelium. The well established antibody CA 19-9 was used for comparison. CA 19-9 showed about the same sensitivity of 88% (BW 494/32: 92%) for ductal pancreatic adenocarcinomas grading I to III. Specificity of CA 19-9, however, was comparable more restricted, as CA 19-9 showed a significant cross-reactivity with other gastrointestinal adenocarcinomas (5 out of 6 colorectal cancers, 3/6 gastric carcinomas, 1/3 carcinomas of the common bile duct), with some extraintestinal cancers (breast 60%, lungs 50%) and with other non-cancerous tissues of intestinal origin. According to the results of this study it is worthwhile to investigate the antibody BW 494/32 for possible applications in experimental immunodiagnosis and -therapy of pancreatic cancer.

Citing Articles

Pancreatic cancer: a review of emerging therapies.

Rosenberg L Drugs. 2000; 59(5):1071-89.

PMID: 10852640 DOI: 10.2165/00003495-200059050-00004.

Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers.

Friess H, Gassmann M, Buchler M Int J Pancreatol. 1997; 21(1):43-52.

PMID: 9127173 DOI: 10.1007/BF02785919.

References

Hsu S, RAINE L, FANGER H . Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-80. DOI: 10.1177/29.4.6166661. View

Haglund C, Roberts P, Kuusela P, Scheinin T, Makela O, Jalanko H . Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer. 1986; 53(2):197-202. PMC: 2001324. DOI: 10.1038/bjc.1986.35. View

Safi F, Beger H, Bittner R, Buchler M, Krautzberger W . CA 19-9 and pancreatic adenocarcinoma. Cancer. 1986; 57(4):779-83. DOI: 10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c. View

Edwards P . Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies. Br J Cancer. 1985; 51(2):149-60. PMC: 1977033. DOI: 10.1038/bjc.1985.24. View

Bosslet K, Kern H, Kanzy E, Steinstraesser A, Schwarz A, Luben G . A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the.... Cancer Immunol Immunother. 1986; 23(3):185-91. PMC: 11038228. DOI: 10.1007/BF00205648. View

Arends J, Verstynen C, Bosman F, Hilgers J, Steplewski Z . Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma. 1983; 2(2):219-29. DOI: 10.1089/hyb.1983.2.219. View

Borowitz M, Tuck F, Sindelar W, Fernsten P, METZGAR R . Monoclonal antibodies against human pancreatic adenocarcinoma: distribution of DU-PAN-2 antigen on glandular epithelia and adenocarcinomas. J Natl Cancer Inst. 1984; 72(5):999-1005. View

Buchler M, Malfertheiner P, Baczako K, Krautzberger W, Beger H . A metastatic endocrine-neurogenic tumor of the ampulla of Vater with multiple endocrine immunoreaction--malignant paraganglioma?. Digestion. 1985; 31(1):54-9. DOI: 10.1159/000199178. View

Gramatzki M, Kalden J . [Monoclonal antibodies in clinical diagnosis and therapy]. Fortschr Med. 1985; 103(36):843-8. View

10.

Walker R, Day S . Expression of the antigen detected by the monoclonal antibody Ca 19.9 in human breast tissues. Virchows Arch A Pathol Anat Histopathol. 1986; 409(3):375-83. DOI: 10.1007/BF00708254. View

11.

Haglund C, Lindgren J, Roberts P, Nordling S . Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer. 1986; 53(2):189-95. PMC: 2001321. DOI: 10.1038/bjc.1986.34. View

12.

Batge B, Bosslet K, Sedlacek H, Kern H, Kloppel G . Monoclonal antibodies against CEA-related components discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias. Virchows Arch A Pathol Anat Histopathol. 1986; 408(4):361-74. DOI: 10.1007/BF00707694. View

13.

Guesdon J, Ternynck T, Avrameas S . The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem. 1979; 27(8):1131-9. DOI: 10.1177/27.8.90074. View

14.

Schmiegel W, Kalthoff H, Arndt R, Gieseking J, Greten H, Kloppel G . Monoclonal antibody-defined human pancreatic cancer-associated antigens. Cancer Res. 1985; 45(3):1402-7. View

15.

Magnani J, Steplewski Z, KOPROWSKI H, Ginsburg V . Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983; 43(11):5489-92. View

16.

Schmiegel W, Kalthoff H . [Monoclonal antibodies against tumor-associated antigens of the gastrointestinal tract. Experimental and clinical outlook]. Dtsch Med Wochenschr. 1985; 110(50):1943-9. DOI: 10.1055/s-2008-1069119. View